Priovant nabs first FDA approval for targeted tablet in dermatomyositis

The FDA approved Priovant Therapeutics' Lisraya (brepocitinib), the first targeted oral TYK2/JAK1 inhibitor for dermatomyositis, with a broad label for all adults with the disease. The approval is based on Phase 3 data showing significant clinical benefit and steroid reduction, positioning the drug for strong sales growth in a rare autoimmune indication.

This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 27 Aug 2026 and 2 Sep 2026.